ATE513819T1 - Neue n-(fluorpyrazinyl)phenylsulfonamide als modulatoren des chemokinrezeptors ccr4 - Google Patents

Neue n-(fluorpyrazinyl)phenylsulfonamide als modulatoren des chemokinrezeptors ccr4

Info

Publication number
ATE513819T1
ATE513819T1 AT06835834T AT06835834T ATE513819T1 AT E513819 T1 ATE513819 T1 AT E513819T1 AT 06835834 T AT06835834 T AT 06835834T AT 06835834 T AT06835834 T AT 06835834T AT E513819 T1 ATE513819 T1 AT E513819T1
Authority
AT
Austria
Prior art keywords
fluoropyrazinyl
phenylsulfonamides
modulators
new
chemokine receptor
Prior art date
Application number
AT06835834T
Other languages
English (en)
Inventor
David Cheshire
Nicholas Kindon
Antonio Mete
Bryan Roberts
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE513819T1 publication Critical patent/ATE513819T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT06835834T 2005-12-12 2006-12-11 Neue n-(fluorpyrazinyl)phenylsulfonamide als modulatoren des chemokinrezeptors ccr4 ATE513819T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502733 2005-12-12
PCT/SE2006/001409 WO2007069978A1 (en) 2005-12-12 2006-12-11 Novel n-(fluoro-pyrazinyl)-phenylsulfonamid.es as moodulators of chemokine receptor ccr4.

Publications (1)

Publication Number Publication Date
ATE513819T1 true ATE513819T1 (de) 2011-07-15

Family

ID=38163190

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06835834T ATE513819T1 (de) 2005-12-12 2006-12-11 Neue n-(fluorpyrazinyl)phenylsulfonamide als modulatoren des chemokinrezeptors ccr4

Country Status (20)

Country Link
US (2) US20080293742A1 (de)
EP (1) EP1968951B1 (de)
JP (1) JP2009519332A (de)
KR (1) KR20080091139A (de)
CN (1) CN101370793B (de)
AR (1) AR058319A1 (de)
AT (1) ATE513819T1 (de)
AU (1) AU2006325573A1 (de)
BR (1) BRPI0619602A2 (de)
CA (1) CA2631342A1 (de)
CL (1) CL2006003449A1 (de)
EC (1) ECSP088603A (de)
ES (1) ES2366807T3 (de)
IL (1) IL191761A0 (de)
NO (1) NO20083070L (de)
RU (1) RU2008122401A (de)
TW (1) TW200730512A (de)
UY (1) UY29999A1 (de)
WO (1) WO2007069978A1 (de)
ZA (1) ZA200804921B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
KR101687144B1 (ko) * 2009-04-22 2016-12-15 액시킨 파마수티컬스 인코포레이티드 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
EP4215209A1 (de) * 2013-09-02 2023-07-26 The University of Melbourne Behandlungsverfahren
CN104402890A (zh) * 2014-11-10 2015-03-11 常州大学 一种制备五氟磺草胺的方法
CN104447756A (zh) * 2014-11-10 2015-03-25 常州大学 一种五氟磺草胺中间体的制备方法
AU2018360766B2 (en) 2017-11-06 2024-09-19 Rapt Therapeutics, Inc. Anticancer agents
CN110028501B (zh) 2018-01-12 2022-02-22 迈德欣国际有限公司 化合物及其制备方法和用途
CN108929279A (zh) * 2018-07-27 2018-12-04 同济大学 一种含氟氨基吡嗪类化合物及其制备方法与应用
CN113893220A (zh) * 2020-07-07 2022-01-07 迈德欣国际有限公司 鼻粘膜给药剂型和其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB928151A (en) * 1959-07-14 1963-06-06 Farmaceutici Italia Pyrazine derivatives
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6638937B2 (en) * 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AU2002358390A1 (en) 2001-12-18 2003-06-30 Astrazeneca Ab Novel compounds
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0302304D0 (sv) * 2003-08-27 2003-08-27 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
AR058319A1 (es) 2008-01-30
CA2631342A1 (en) 2007-06-21
ECSP088603A (es) 2008-08-29
BRPI0619602A2 (pt) 2011-10-11
ES2366807T3 (es) 2011-10-25
KR20080091139A (ko) 2008-10-09
HK1121760A1 (en) 2009-04-30
EP1968951B1 (de) 2011-06-22
RU2008122401A (ru) 2010-01-20
EP1968951A1 (de) 2008-09-17
CN101370793A (zh) 2009-02-18
ZA200804921B (en) 2009-09-30
US20100144759A1 (en) 2010-06-10
NO20083070L (no) 2008-08-28
UY29999A1 (es) 2007-07-31
CN101370793B (zh) 2012-01-04
AU2006325573A1 (en) 2007-06-21
TW200730512A (en) 2007-08-16
IL191761A0 (en) 2008-12-29
JP2009519332A (ja) 2009-05-14
US20080293742A1 (en) 2008-11-27
CL2006003449A1 (es) 2008-02-08
WO2007069978A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
DK2060570T3 (da) Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater
ATE476424T1 (de) Diazepanderivate als modulatoren von chemokinrezeptoren
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
ATE516274T1 (de) Neue verbindungen als modulatoren des opioidrezeptors
DE60305903D1 (de) Tropanderivative als ccr5-modulatoren
ATE533743T1 (de) Harnstoffderivate von aminotetralin als modulatoren des vanilloid-rezeptors vr1
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
DE602006010546D1 (de) N-(pyridin-2-yl)sulfonamidderivate
ATE545631T1 (de) N-(2-benzyl)-2-phenylbutanamide als androgenrezeptormodulatoren
ATE510831T1 (de) Hydrierte benzoäcüthiophenderivate als immunmodulatoren
ATE487717T1 (de) Imidazo- und triazolopyridine als inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
DE502007000290D1 (de) Neue Verwendungen von Nonenolid
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
EP1852679A4 (de) Oszillierender kreiselsensor
ATE549333T1 (de) Neue sulfonylpyrrole als hdac-inhibitoren
EP1841794A4 (de) Adam-9-modulatoren
MA28580B1 (fr) 3-(4-hétéroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de récepteurs de chimiokines
EP1871752A4 (de) Antagonisten des amidopropoxyphenylorexinrezeptors
ZA200804921B (en) Novel N-(fluoro-pyrazinyl)-phenylsulfonamides as modulators of chemokine receptor CCR4
DE602006004463D1 (de) Kristallform von asenapinmaleat
DE602004023529D1 (de) Regelung der Güte (Q) von Filtern
FI20055089A0 (fi) Liikeratanosturi
EP1970076A4 (de) Pharmazeutische zusammensetzung zum auftragen auf einen nagel
DE602005024107D1 (de) Flüssigkristall wiedergabeanordnung
EP1827473A4 (de) Modulator von alpha-synuclein-toxizität

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties